What is the rationale for novel combination therapies?
Niels van de Donk
Do immunoglobulin receptor interactions play a role in CLL?
Highlights from ASH 2016: deintensifying chemotherapy for children with ALL
Novel PD-1 inhibitor and BTK inhibitor combination: tislelizumab and zanubrutinib
Combining CLL drugs to overcome the problem of resistance